Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants

Antiviral Research
Natalia A IlyushinaElena A Govorkova

Abstract

Rapid development of resistant influenza variants after amantadine treatment is one of the main drawbacks of M2 blockers. On the other hand, the emergence of variants with low susceptibility to the neuraminidase (NA) inhibitors is limited. In the present study we examined whether combination therapy with two classes of anti-influenza drugs can affect the emergence of resistant variants in vitro. We observed that virus yields of human A/Nanchang/1/99 (H1N1), A/Panama/2007/99 (H3N2), and A/Hong Kong/156/97 (H5N1) viruses in MDCK cells were significantly reduced (P<0.005) when the cells were treated with the combination of amantadine and low doses of oseltamivir carboxylate (< or =1microM). After five sequential passages in MDCK cells, the M2 protein of viruses cultivated with amantadine alone mutated at positions V27A and S31N/I. Viruses cultivated with oseltamivir carboxylate (> or =0.001microM) possessed mutations in the hemagglutinin (HA) protein. These variants showed reduced efficiency of binding to sialic acid receptors and decreased sensitivity to NA inhibitor in plaque reduction assay. Importantly, no mutations in the HA, NA, and M2 proteins were detected when the drugs were used in combination. Our results suggest that c...Continue Reading

References

May 1, 1992·Cell·L H PintoR A Lamb
Sep 1, 1992·Journal of Virological Methods·A S Gambaryan, M N Matrosovich
Apr 1, 1980·Antimicrobial Agents and Chemotherapy·S Z WilsonR B Couch
May 1, 1980·Antimicrobial Agents and Chemotherapy·F G HaydenR G Douglas
Oct 1, 1980·Antimicrobial Agents and Chemotherapy·F G HaydenR Simons
May 20, 1998·Antiviral Research·C ScholtissekR G Webster
Oct 21, 1998·The Journal of Infectious Diseases·L V GubarevaR G Webster
Sep 9, 1999·The Journal of Infectious Diseases·T ZieglerN J Cox
Aug 9, 2001·The European Respiratory Journal·I Stephenson, K G Nicholson
Jan 29, 2002·Archives of Virology·E HoffmannD R Perez
Jun 26, 2003·The Journal of Infectious Diseases·Kyoko ShiraishiYoshihiro Kawaoka
Feb 27, 2004·The New England Journal of Medicine·Tinh Hien TranUNKNOWN World Health Organization International Avian Influenza Investigative Team
Oct 13, 2004·The Journal of Infectious Diseases·M Louise HerlocherArnold S Monto
Nov 25, 2004·Antimicrobial Agents and Chemotherapy·Elena A GovorkovaRobert G Webster

❮ Previous
Next ❯

Citations

Apr 14, 2007·Medical Microbiology and Immunology·Jindrich CinatlHans W Doerr
Mar 29, 2008·Archives of Virology·Christopher LupferManoj Pastey
Nov 1, 2013·The Journal of Microbiology·Sangmoo LeeMan-Seong Park
Dec 1, 2007·Nature Reviews. Drug Discovery·Mark von Itzstein
Apr 13, 2010·Nature Structural & Molecular Biology·Kalyan DasEddy Arnold
Dec 17, 2008·The New England Journal of Medicine·W Paul Glezen
Nov 14, 2008·Proceedings of the National Academy of Sciences of the United States of America·Rupert J RussellJohn J Skehel
Nov 27, 2008·Proceedings of the National Academy of Sciences of the United States of America·Yorgo Modis
Aug 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Stephen D C Griffin
Mar 28, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gregory A PolandInna G Ovsyannikova
Feb 18, 2009·European Journal of Public Health·Douglas M FlemingW John Paget
Mar 20, 2010·The Journal of Antimicrobial Chemotherapy·James R Smith
Jul 31, 2008·The Pediatric Infectious Disease Journal·William Paul Glezen
Nov 11, 2009·Antimicrobial Agents and Chemotherapy·Donald F SmeeYousuke Furuta
May 26, 2010·Antimicrobial Agents and Chemotherapy·Ashley N BrownGeorge L Drusano
Aug 30, 2008·Antimicrobial Agents and Chemotherapy·Natalia A IlyushinaElena A Govorkova
Apr 13, 2007·Clinical Microbiology Reviews·J S Malik PeirisYi Guan
Jan 18, 2013·Journal of Virology·Tatiana BaranovichElena A Govorkova
Aug 3, 2007·Doklady Biological Sciences : Proceedings of the Academy of Sciences of the USSR, Biological Sciences Sections·I N ZhilinskayaI P Ashmarin
Feb 10, 2007·BMJ : British Medical Journal·Sotirios TsiodrasAngelos Hatzakis
Oct 18, 2007·Annual Review of Medicine·Anne Moscona
Jan 27, 2007·PLoS Medicine·Marc LipsitchBruce R Levin
Sep 25, 2010·PLoS Pathogens·Maki KisoYoshihiro Kawaoka
Aug 31, 2010·Paediatric Drugs·Steven M Smith, John G Gums
Jul 10, 2010·Drugs·David A BoltzElena A Govorkova
Apr 9, 2014·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·Lev L GladkovAli A El-Emam
Apr 5, 2014·Cellular and Molecular Life Sciences : CMLS·Arianna LoregianGiorgio Palù
Sep 13, 2014·The Lancet Infectious Diseases·Jake DunningUNKNOWN International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC)
Nov 4, 2008·Current Opinion in Infectious Diseases·Angie LackenbyJane Democratis
Dec 5, 2006·Expert Review of Anti-infective Therapy·Aeron C HurtIan Barr

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.